Drug Trial Radar · NCT06016972
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Mar 5, 2024
Primary completion
Aug 20, 2024
Study completion Aug 20, 2024
Sponsor
- Lead sponsor
- Qlaris Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
Conditions
- Primary Open Angle Glaucoma (POAG)
- Primary Open Angle Glaucoma of Both Eyes
- Primary Open-Angle Glaucoma, Unspecified Eye
- Ocular Hypertension (OHT)
Interventions
Experimental: QLS-111 ophthalmic solution, (0.015%)Drug
QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Experimental: QLS-111 ophthalmic solution, (0.03%)Drug
QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Experimental: QLS-111 ophthalmic solution, (0.075%)Drug
QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
QLS-111 ophthalmic vehicle solutionOther
Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)Time frame: 21 days
- Clinically significant change in visual acuityTime frame: 21 days
- Clinically significant change in findings on slit lamp examTime frame: 21 days
- Clinically significant change in findings on fundus examTime frame: 21 days
- Incidence of systemic TEAEsTime frame: 21 days
- Clinically significant changes in blood pressure (BP)Time frame: 21 days
- Clinically significant changes in heart rate (HR)Time frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Coastal Research Associates, LLC
Roswell, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.